PGIM India Healthcare Fund Direct Growth

Fund Overview

Fund Size

₹95 Cr

Expense Ratio

0.80%

ISIN

INF663L01Z45

Minimum SIP

₹1,000

Exit Load

No Charges

Inception Date

06 Dec 2024

About this fund

PGIM India Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by PGIM India Mutual Fund. This fund has been in existence for 1 years, 6 months and 16 days, having been launched on 06-Dec-24.
As of 19-Jun-26, it has a Net Asset Value (NAV) of ₹11.38, Assets Under Management (AUM) of 95.49 Crores, and an expense ratio of 0.8%.

PGIM India Healthcare Fund Direct Growth has given a CAGR return of 8.80% since inception.
The fund's asset allocation comprises around 97.90% in equities, 0.00% in debts, and 2.10% in cash & cash equivalents.
You can start investing in PGIM India Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+17.44%

+13.67% (Cat Avg.)

Since Inception

+8.80%

— (Cat Avg.)

Portfolio Summaryas of 31st May 2026

Equity	₹93.49 Cr	97.90%
Others	₹2.01 Cr	2.10%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹10.83 Cr	11.34%
Divi's Laboratories Ltd	Equity	₹9.56 Cr	10.01%
J.B. Chemicals & Pharmaceuticals Ltd	Equity	₹6.24 Cr	6.53%
Aster DM Healthcare Ltd Ordinary Shares	Equity	₹6.15 Cr	6.44%
Rubicon Research Ltd	Equity	₹5.7 Cr	5.97%
Mankind Pharma Ltd	Equity	₹5 Cr	5.24%
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹4.75 Cr	4.97%
Ajanta Pharma Ltd	Equity	₹4.47 Cr	4.68%
Krishna Institute of Medical Sciences Ltd	Equity	₹3.96 Cr	4.15%
Dr. Lal PathLabs Ltd	Equity	₹3.12 Cr	3.27%
Neuland Laboratories Ltd	Equity	₹3.03 Cr	3.17%
Navin Fluorine International Ltd	Equity	₹2.96 Cr	3.10%
Abbott India Ltd	Equity	₹2.79 Cr	2.92%
Dr Reddy's Laboratories Ltd	Equity	₹2.61 Cr	2.73%
Torrent Pharmaceuticals Ltd	Equity	₹2.54 Cr	2.66%
Sai Life Sciences Ltd	Equity	₹2.52 Cr	2.64%
Anthem Biosciences Ltd	Equity	₹2.09 Cr	2.19%
Jupiter Life Line Hospitals Ltd	Equity	₹1.99 Cr	2.08%
Clearing Corporation Of India Ltd.	Cash - Repurchase Agreement	₹1.83 Cr	1.92%
Global Health Ltd	Equity	₹1.73 Cr	1.81%
Cipla Ltd	Equity	₹1.56 Cr	1.63%
Fortis Healthcare Ltd	Equity	₹1.41 Cr	1.47%
PB Fintech Ltd	Equity	₹1.31 Cr	1.37%
Lupin Ltd	Equity	₹1.29 Cr	1.35%
Pfizer Ltd	Equity	₹1.26 Cr	1.32%
ICICI Lombard General Insurance Co Ltd	Equity	₹1.1 Cr	1.15%
Dr Agarwal’s Health Care Ltd	Equity	₹1.01 Cr	1.06%
Orchid Pharma Ltd	Equity	₹0.82 Cr	0.85%
Lenskart Solutions Ltd	Equity	₹0.71 Cr	0.74%
Sagility Ltd	Equity	₹0.5 Cr	0.53%
Dr Agarwal'S Eye Hospital Ltd	Equity	₹0.49 Cr	0.52%
Net Receivables / (Payables)	Cash	₹0.17 Cr	0.18%

Allocation By Market Cap (Equity)

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹88.12 Cr	92.28%
Basic Materials	₹2.96 Cr	3.10%
Financial Services	₹2.4 Cr	2.52%

Risk & Performance Ratios

Fund Managers

Puneet Pal

Since January 2025

Anandha Padmanabhan Anjeneyan

Since January 2025

Utsav Mehta

Since January 2025

Vivek Sharma

Since January 2025

Additional Scheme Detailsas of 31st May 2026

ISIN

INF663L01Z45

Expense Ratio

0.80%

Exit Load

No Charges

Fund Size

₹95 Cr

Age

1 year 6 months

Lumpsum Minimum

₹5,000

Fund Status

Open Ended Investment Company

Benchmark

BSE Healthcare TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Groww BSE Hospitals ETF Very High Risk	0.5%	-	₹50.02 Cr	-
Mirae Asset Nifty 500 Healthcare ETF Very High Risk	0.1%	-	₹12.06 Cr	-
Bandhan Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹310.92 Cr	-
Bandhan Healthcare Fund Regular Growth Very High Risk	2.1%	0.0%	₹310.92 Cr	-
Baroda BNP Paribas Health and Wellness Fund Direct Growth Very High Risk	0.6%	1.0%	₹544.17 Cr	-
Baroda BNP Paribas Health and Wellness Fund Regular Growth Very High Risk	2.1%	1.0%	₹544.17 Cr	-
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk	2.1%	1.0%	₹332.52 Cr	13.1%
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk	0.7%	1.0%	₹332.52 Cr	15.0%
PGIM India Healthcare Fund Direct Growth Very High Risk	0.8%	0.0%	₹95.49 Cr	17.4%
PGIM India Healthcare Fund Regular Growth Very High Risk	2.5%	0.0%	₹95.49 Cr	15.4%
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk	2.0%	0.0%	₹664.02 Cr	18.6%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk	0.6%	0.0%	₹664.02 Cr	20.7%
DSP Nifty Healthcare ETF Regular Growth Very High Risk	0.2%	-	₹14.94 Cr	12.7%
Kotak Healthcare Fund Direct Growth Very High Risk	0.9%	0.0%	₹560.17 Cr	21.8%
Kotak Healthcare Fund Regular Growth Very High Risk	2.5%	0.0%	₹560.17 Cr	19.8%
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk	2.0%	1.0%	₹2362.44 Cr	22.8%
HDFC Pharma and Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹2362.44 Cr	24.2%
Nippon India Pharma Fund Direct Growth Very High Risk	0.8%	1.0%	₹8635.75 Cr	9.0%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Regular Growth Very High Risk	1.6%	1.0%	₹6453.52 Cr	8.9%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth Very High Risk	0.9%	1.0%	₹6453.52 Cr	9.9%
DSP Healthcare Fund Direct Growth Very High Risk	0.5%	0.0%	₹3309.17 Cr	9.8%
DSP Healthcare Fund Regular Growth Very High Risk	1.7%	0.0%	₹3309.17 Cr	8.3%
LIC MF Healthcare Fund Direct Growth Very High Risk	1.0%	1.0%	₹88.96 Cr	11.9%
LIC MF Healthcare Fund Regular Growth Very High Risk	2.1%	1.0%	₹88.96 Cr	10.4%
quant Healthcare Fund Direct Growth Very High Risk	0.8%	1.0%	₹372.50 Cr	11.6%
quant Healthcare Fund Regular Growth Very High Risk	2.5%	1.0%	₹372.50 Cr	9.8%
UTI Healthcare Fund Direct Growth Very High Risk	1.2%	1.0%	₹1216.85 Cr	15.1%
SBI Healthcare Opportunities Fund Direct Growth Very High Risk	0.9%	0.0%	₹4565.95 Cr	15.8%
Tata India Pharma & Healthcare Fund Regular Growth Very High Risk	1.8%	0.0%	₹1386.99 Cr	8.3%
Tata India Pharma & Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹1386.99 Cr	9.9%
ICICI Prudential Nifty Healthcare ETF Very High Risk	0.1%	-	₹202.94 Cr	12.8%
SBI Healthcare Opportunities Fund Regular Growth Very High Risk	1.9%	0.0%	₹4565.95 Cr	14.6%
Nippon India Pharma Fund Regular Growth Very High Risk	1.5%	1.0%	₹8635.75 Cr	8.1%
UTI Healthcare Fund Regular Growth Very High Risk	2.2%	1.0%	₹1216.85 Cr	14.0%
Axis NIFTY Healthcare ETF Very High Risk	0.4%	-	₹22.75 Cr	12.6%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹1570.17 Cr	14.8%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	1.7%	1.0%	₹3090.51 Cr	14.9%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.4%	1.0%	₹3090.51 Cr	16.5%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹237.99 Cr	6.1%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹237.99 Cr	8.1%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹76.47 Cr	12.8%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	1.9%	1.0%	₹950.31 Cr	14.2%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	0.8%	1.0%	₹950.31 Cr	15.7%
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.3%	-	₹39.76 Cr	12.3%

About the AMC

PGIM India Mutual Fund

+91 22 61593000

https://www.pgimindiamf.com/

Total AUM

₹26,681 Cr

Address

Nirlon House, 2nd Floor, Mumbai, 400 030

Other Funds by PGIM India Mutual Fund

Fund name	Expense Ratio	Exit Load	Fund size	1Y
PGIM India Multi Asset Allocation Fund Direct Growth Very High Risk	0.6%	0.0%	₹273.65 Cr	-
PGIM India Healthcare Fund Direct Growth Very High Risk	0.8%	0.0%	₹95.49 Cr	17.4%
PGIM India Multi Cap Fund Direct Growth Very High Risk	0.8%	0.0%	₹413.64 Cr	9.8%
PGIM India Retirement Fund Direct Growth Very High Risk	1.0%	0.0%	₹98.56 Cr	3.7%
PGIM India Large and Mid Cap Fund Direct Growth Very High Risk	0.7%	0.0%	₹781.86 Cr	2.5%
PGIM India Fixed Duration Fund - Series BH Direct Growth Moderate Risk	-	0.0%	-	-
PGIM India Fixed Duration Fund - Series BJ Direct Growth Moderate Risk	-	0.0%	-	-
PGIM India Fixed Duration Fund - Series BI Direct Growth Moderate Risk	-	0.0%	-	-
PGIM India Fixed Duration Fund - Series BF Direct Growth Moderate Risk	-	0.0%	-	-
PGIM India Fixed Duration Fund - Series BG Direct Growth Moderate Risk	-	0.0%	-	-
PGIM India Overnight Fund Direct Growth Low Risk	0.2%	0.0%	₹63.33 Cr	5.2%
PGIM India Dynamic Bond Direct Growth Moderate Risk	0.5%	0.0%	₹82.67 Cr	3.6%
PGIM India Global Select Real Estate Securities Fund of Fund Direct Growth Very High Risk	1.5%	0.0%	₹59.53 Cr	20.6%
PGIM India Balanced Advantage Fund Direct Growth Moderately High risk	0.7%	0.0%	₹797.63 Cr	0.7%
PGIM India CRISIL IBX Gilt Index - Apr 2028 Fund Direct Growth Low to Moderate Risk	0.5%	0.0%	₹21.62 Cr	5.2%
PGIM India Flexi Cap Fund Direct Growth Very High Risk	0.6%	0.0%	₹5732.98 Cr	3.3%
PGIM India Gilt Fund Direct Growth Moderate Risk	0.6%	0.0%	₹92.58 Cr	1.8%
PGIM India Global Equity Opportunities Fund Direct Growth Very High Risk	1.4%	0.0%	₹1797.44 Cr	31.2%
PGIM India Emerging Markets Equity Fund Direct Growth Very High Risk	1.3%	0.0%	₹1490.48 Cr	57.1%
PGIM India Liquid Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹612.44 Cr	6.4%
PGIM India Low Duration Fund Direct Growth Low to Moderate Risk	0.4%	0.0%	₹93.31 Cr	7.2%
PGIM India Corporate Bond Fund Direct Growth Moderate Risk	0.3%	0.0%	₹85.46 Cr	5.0%
PGIM India Hybrid Equity Fund Direct Growth High Risk	0.8%	0.0%	₹201.84 Cr	2.9%
PGIM India Large Cap Fund Direct Growth Very High Risk	0.9%	0.0%	₹534.93 Cr	-0.4%
PGIM India Short Duration Fund Direct Growth Low to Moderate Risk	0.3%	0.0%	₹27.94 Cr	6.7%
PGIM India Ultra Short Duration Fund Direct Growth Low to Moderate Risk	0.3%	0.0%	₹174.73 Cr	6.1%
PGIM India Equity Savings Fund Direct Growth Moderate Risk	0.6%	0.0%	₹59.57 Cr	3.8%
PGIM India Arbitrage Fund Direct Growth Low Risk	0.4%	0.0%	₹92.17 Cr	6.2%
PGIM India Money Market Fund Direct Growth Low to Moderate Risk	0.2%	0.0%	₹142.21 Cr	6.1%
PGIM India ELSS Tax Saver Fund Direct Growth Very High Risk	0.9%	0.0%	₹688.59 Cr	0.8%
PGIM India Midcap Opportunities Fund Direct Growth Very High Risk	0.6%	0.0%	₹10821.62 Cr	4.2%
PGIM India Credit Risk Fund Segregated Plan 1 Direct Growth Low to Moderate Risk	-	0.0%	-	-
PGIM India Banking and PSU Debt fund Direct Growth Moderate Risk	0.2%	0.0%	₹45.38 Cr	6.8%
PGIM India Small Cap Fund Direct Growth Very High Risk	0.7%	0.0%	₹1567.38 Cr	13.1%

Risk Level

Your principal amount will be at Very High Risk

Take control of your wealth

Track and Analyse all your investments with Dezerv

Rated ★ 4.3+ on

Still got questions?
We're here to help.

What is the current NAV of PGIM India Healthcare Fund Direct Growth?

The NAV of PGIM India Healthcare Fund Direct Growth, as of 19-Jun-2026, is ₹11.38.

What is the portfolio composition of PGIM India Healthcare Fund Direct Growth?

The fund's allocation of assets is distributed as 97.90% in equities, 0.00% in bonds, and 2.10% in cash and cash equivalents.

Who manages the PGIM India Healthcare Fund Direct Growth?

The fund managers responsible for PGIM India Healthcare Fund Direct Growth are:-

Puneet Pal
Anandha Padmanabhan Anjeneyan
Utsav Mehta
Vivek Sharma

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

©2021-2026 Dezerv. All Rights Reserved

Dezerv Investments Pvt. Ltd. is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.

Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.

PGIM India Healthcare Fund Direct Growth

Fund Overview